Asimos Andrew W, Norton H James, Price Marlow F, Cheek Wilkie M
Department of Emergency Medicine, Carolinas Medical Center, PO Box 32861, Charlotte, NC 28232, USA.
Acad Emerg Med. 2004 Apr;11(4):361-70. doi: 10.1197/j.aem.2003.12.016.
To describe the experience of a community teaching hospital emergency department (ED) Code Stroke Protocol (CSP) for identifying acute ischemic stroke (AIS) patients and treating them with tissue plasminogen activator (tPA) and to compare outcome measures with those achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial.
This study was a retrospective review from a hospital CSP registry.
Over a 56-month period, CSP activation occurred 255 times, with 24% (n = 60) of patients treated with intravenous (IV) tPA. The most common reasons for thrombolytic therapy exclusion were mild or rapidly improving symptoms in 37% (n = 64), intracerebral hemorrhage (ICH) in 23% (n = 39), and unconfirmed symptom onset time for 14% (n = 24) of patients. Within 36 hours of IV tPA treatment, 10% (NINDS = 6%) of patients (n = 6) sustained a symptomatic ICH (SICH). Three months after IV tPA treatment, 60% of patients had achieved an excellent neurologic outcome, based on a Barthel Index of > or =95 (NINDS = 52%), while mortality measured 12% (NINDS = 17%). Among IV tPA-treated patients, those developing SICH were significantly older and had a significantly higher mean initial glucose value. Treatment protocol violations occurred in 32% of IV tPA-treated patients but were not significantly associated with SICH (Fisher's exact test).
Over the study period, the CSP yielded approximately one IV tPA-treated patient for every four screened and, despite prevalent protocol violations, attained three-month functional outcomes equal to those achieved in the NINDS trial. For community teaching hospitals, ED-directed CSPs are a feasible and effective means to screen AIS patients for treatment with thrombolysis.
描述一家社区教学医院急诊科的卒中急救方案(CSP)用于识别急性缺血性卒中(AIS)患者并使用组织纤溶酶原激活剂(tPA)进行治疗的经验,并将结果指标与美国国立神经疾病和卒中研究所(NINDS)试验所取得的结果进行比较。
本研究是对医院CSP登记处进行的回顾性分析。
在56个月的时间里,CSP启动了255次,24%(n = 60)的患者接受了静脉注射(IV)tPA治疗。溶栓治疗排除的最常见原因是症状轻微或迅速改善,占37%(n = 64);脑出血(ICH)占23%(n = 39);14%(n = 24)的患者症状发作时间未得到确认。在静脉注射tPA治疗的36小时内,10%(NINDS为6%)的患者(n = 6)发生了有症状的脑出血(SICH)。静脉注射tPA治疗三个月后,根据巴氏指数≥95,60%的患者获得了良好的神经功能结果(NINDS为52%),而死亡率为12%(NINDS为17%)。在接受静脉注射tPA治疗的患者中,发生SICH的患者年龄明显更大,初始血糖平均值明显更高。32%接受静脉注射tPA治疗的患者出现了治疗方案违规,但与SICH无显著相关性(Fisher精确检验)。
在研究期间,CSP每筛查四名患者约有一名接受静脉注射tPA治疗,尽管普遍存在方案违规情况,但三个月的功能结果与NINDS试验所取得的结果相当。对于社区教学医院而言,急诊科主导的CSP是筛查AIS患者进行溶栓治疗的一种可行且有效的方法。